Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Acquisitions (2016 - 2025)

Historic Acquisitions for Gsk (GLAXF) over the last 14 years, with Q4 2025 value amounting to -$49.2 million.

  • Gsk's Acquisitions rose 9487.41% to -$49.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$2.2 billion, marking a year-over-year decrease of 1579.69%. This contributed to the annual value of -$2.2 billion for FY2025, which is 11683.85% down from last year.
  • According to the latest figures from Q4 2025, Gsk's Acquisitions is -$49.2 million, which was up 9487.41% from -$1.2 billion recorded in Q3 2025.
  • In the past 5 years, Gsk's Acquisitions registered a high of -$36.6 million during Q2 2024, and its lowest value of -$1.7 billion during Q4 2023.
  • Moreover, its 4-year median value for Acquisitions was -$912.1 million (2024), whereas its average is -$669.2 million.
  • Per our database at Business Quant, Gsk's Acquisitions tumbled by 179791.43% in 2023 and then surged by 9487.41% in 2025.
  • Gsk's Acquisitions (Quarter) stood at -$91.5 million in 2022, then crashed by 1797.91% to -$1.7 billion in 2023, then soared by 44.71% to -$960.1 million in 2024, then surged by 94.87% to -$49.2 million in 2025.
  • Its last three reported values are -$49.2 million in Q4 2025, -$1.2 billion for Q3 2025, and -$1.0 billion during Q1 2025.